| |
Highlights from the Joint 15th Congress of the European CanCer Organisation and the 34th Congress of the European Society for Medical Oncology
Expert Perspectives with John Crown, MD
Interview conducted by Sunil Verma, MD, MSEd, FRCPC
 |
John Crown, MD
St Vincent's University Hospital
Elm Park, Dublin, Ireland |
 |
Sunil Verma, MD, MSEd, FRCPC
Toronto-Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada |
This independent medical education activity features an expert interview with John Crown, MD, that focuses on important data from the following abstracts presented in Berlin:
Abstract #5000: A Multicenter Randomised Phase II Clinical Trial Exploring Oral Vinorelbine and Capecitabine in Combination or in Alternating Sequence Versus Docetaxel and Capecitabine in Combination in 1st Line Treatment of Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines
Campone M, Dobrovolskaya N, Tjulandin S, Chen S-C, Fourié S-J, Mefti F, Konstantinova M, Pouget J-C, Lefresne F, Jassem J
Abstract #5001: CIRG/TORI 010: Primary Analysis of a Randomized, Placebo Controlled, Phase II Trial of Motesanib Plus Weekly Paclitaxel as First-Line Therapy in HER2-Negative Metastatic Breast Cancer
Martin M, Hurvitz S, Kennedy J, Forbes J, Roché H, Pinter T, Eiermann W, Buyse M, Rupin M, Mackey J
Abstract #5003: Phase II Study of Sunitinib in Combination with Trastuzumab for the Treatment of Metastatic Breast Cancer: Activity and Safety Result
Blay JY, Lluch A, Gutierrez M, Martin M, Kozloff MF, Prady C, Tassell V, Kern K, Huang X, Verma S
Disclaimer: The information on this site is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice.
This Webcast is available from December 2009 to December 2010.
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
|
|
